Nestlé CA2912957 Refused: Cartilage Composition Claims Anticipated and Obvious
Canada’s Patent Appeal Board recommended refusal of Nestlé Products Company SA’s application CA2912957, covering compositions for use in cartilage breakdown. All 16 claims were found either anticipated or obvious under the Patent Act, with the Commissioner formally refusing the application on 8 October 2024.
All 16 Nestlé Cartilage Composition Claims Fail at Patent Appeal Board
Nestlé Products Company SA, represented by Marks & Clerk Canada, pursued patent application CA2912957A1 before the Canadian Intellectual Property Office (CIPO), seeking protection for compositions for use in cartilage breakdown. The application was examined and rejected under subsection 199(1) of the Patent Rules before being referred to the Patent Appeal Board for review under paragraph 86(7)(c).
The Patent Appeal Board recommended refusal of the application, concluding that claims 1, 2, and 4 to 16 were anticipated contrary to paragraph 28.2(1)(b) of the Patent Act, and that all claims 1 to 16 were obvious contrary to section 28.3. Nestlé’s proposed amended claims were found insufficient to render the application allowable and therefore ineligible as necessary amendments under subsection 86(11) of the Patent Rules. The Commissioner of Patents adopted the Board’s recommendation and formally refused the application on 8 October 2024.
The dual finding of both anticipation and obviousness across the entire claim set suggests the prior art landscape in this cartilage-related composition space was well-populated at the relevant date. The public record does not disclose which specific prior art references were determinative, nor the precise technical distinction Nestlé sought to establish. With the application refused rather than abandoned, Nestlé retains the right to appeal the Commissioner’s decision to the Federal Court of Canada under section 41 of the Patent Act.
Filing to Unpatentable in 0 days
Closed 8 October 2024 — CIPO Patent Appeal Board review
Application refused: what the Patent Appeal Board’s decision means
Anticipation and obviousness: a dual refusal
Under paragraph 28.2(1)(b) of the Canadian Patent Act, a claim is anticipated if the subject matter was disclosed before the claim date in a manner enabling a skilled person to practise it. Under section 28.3, a claim is obvious if it would have been plain to a person skilled in the art. The Board found both defects across the entire 16-claim set — a particularly broad adverse finding that left no surviving claim.
All 16 claims invalidatedNestlé loses all claims; Federal Court appeal remains available
The Commissioner’s refusal means CA2912957A1 will not issue as a granted patent. Nestlé’s proposed amended claims were expressly rejected as insufficient. However, a Commissioner’s refusal is not final — under section 41 of the Patent Act, Nestlé may appeal to the Federal Court of Canada. The public record does not indicate whether such an appeal has been filed.
Appeal to Federal Court possiblePrior art density in cartilage composition space confirmed
The Board’s findings of anticipation and obviousness across all claims suggest a crowded prior art field for cartilage-related compositions at the relevant priority date. Competitors and R&D teams working in nutraceutical or pharmaceutical cartilage health formulations may take this as a signal that broad composition claims in this area face a high patentability bar before CIPO.
Crowded prior art landscapeNo patent exclusivity for these cartilage compositions in Canada
With CA2912957A1 refused, Nestlé cannot enforce patent rights over these specific cartilage breakdown compositions in Canada. Competitors marketing similar compositions are not subject to exclusivity risk from this application. Any freedom-to-operate analysis referencing CA2912957A1 should note that it will not proceed to grant unless the Federal Court reverses the Commissioner’s decision.
No enforceable patent grantedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nestlé Products Company SA | Company | Nestlé Products Company SA — global nutrition and health company, applicant for CA2912957A1Search in Eureka ↗ |
| Defendant | Defendant | Individual | N/A — ex parte CIPO Patent Appeal Board proceeding; no opposing defendant partySearch in Eureka ↗ |
| Plaintiff law firm | Marks & Clerk Canada | Law Firm | Representing Nestlé Products Company SASearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | CIPOSearch in Eureka ↗ |
Official order — verbatim text
The Board’s recommendation targets both anticipation (claims 1, 2, 4–16 under s.28.2(1)(b)) and obviousness (all 16 claims under s.28.3), with the Commissioner formally adopting the refusal. The express rejection of Nestlé’s proposed amended claims as failing the ‘necessary amendment’ threshold under s.86(11) forecloses amendment as a remedy at this stage. The combined finding leaves no surviving pathway within the CIPO process, making a Federal Court appeal the only remaining avenue for Nestlé.
CA2912957A1 — Compositions for Use in Cartilage Breakdown
CA2912957A1 is a Canadian patent application filed by Nestlé Products Company SA covering compositions for use in cartilage breakdown. The application was prosecuted before CIPO and ultimately referred to the Patent Appeal Board after rejection under subsection 199(1) of the Patent Rules. The 16 claims collectively sought to define the composition scope, likely spanning ingredient combinations or formulations relevant to joint health or cartilage metabolism.
Cartilage breakdown compositions sit at the intersection of nutraceutical, functional food, and pharmaceutical IP — a space where Nestlé and other large nutrition companies have historically pursued broad protection. The Board’s finding that prior art anticipated and rendered obvious the claimed compositions suggests competitors had already established relevant disclosures in this area before the application’s claim date. For companies developing joint health or cartilage-support products, the refusal of this application reduces one potential enforcement risk but does not eliminate Nestlé’s broader IP presence in the nutrition sector.
Should you run an FTO against CA2912957A1?
Product teams and R&D leaders developing cartilage health compositions, joint support formulations, or related nutraceuticals for the Canadian market should note that CA2912957A1 has been refused and will not proceed to grant absent a successful Federal Court appeal. This reduces the immediate exclusivity risk from this specific application. However, teams should verify whether a Federal Court appeal has been filed and monitor Nestlé’s broader Canadian patent portfolio for related granted patents covering similar subject matter.
PatSnap Eureka’s FTO Search Agent can scan Nestlé’s full Canadian patent portfolio, identify related applications in the cartilage and joint health composition space, and flag any granted patents with claims that could overlap with your formulation. By combining prosecution history analysis with claim mapping, Eureka helps R&D and legal teams build a defensible clearance position before product launch in Canada.
Run a freedom-to-operate analysis on CA2912957A1 to assess your product’s exposure
Run FTO in Eureka →Similar CIPO Patent Appeal Board Refusals: Composition & Nutraceutical Cases
Explore Patent Appeal Board decisions at CIPO involving composition and nutraceutical patent applications refused on anticipation or obviousness grounds.
What this refusal signals for nutraceutical composition IP in Canada
The Board’s dual anticipation and obviousness findings across all 16 claims highlight the challenges of securing broad composition patents before CIPO in health and nutrition.
Broad composition claims in cartilage health face a high CIPO bar
The Patent Appeal Board’s rejection of all 16 claims on both anticipation and obviousness grounds suggests that the prior art in cartilage-related health compositions was well-developed before CA2912957’s priority date. Applicants in adjacent nutraceutical and functional food spaces should expect rigorous prior art scrutiny from CIPO examiners.
Federal Court appeal is Nestlé’s remaining procedural lever
A Commissioner’s refusal under CIPO’s Patent Appeal Board process is not necessarily the end of the road. Section 41 of the Patent Act provides a route to the Federal Court of Canada. Monitoring whether Nestlé pursues this avenue will be relevant for competitors tracking exclusivity risk around cartilage composition formulations in Canada.
Nestlé v Defendant — key questions answered
The Patent Appeal Board found that claims 1, 2, and 4 to 16 were anticipated under paragraph 28.2(1)(b) of the Canadian Patent Act, and that all 16 claims were obvious under section 28.3. Nestlé’s proposed amended claims were also rejected as failing to meet the ‘necessary amendment’ threshold under subsection 86(11) of the Patent Rules. The Commissioner formally refused the application on 8 October 2024.
The refusal means CA2912957A1 will not issue as a granted Canadian patent, leaving Nestlé without patent exclusivity over these specific cartilage breakdown compositions in Canada. Competitors are not subject to enforcement risk from this application. Nestlé may appeal to the Federal Court of Canada under section 41 of the Patent Act, but no appeal has been confirmed in the public record.
Yes. Under section 41 of the Canadian Patent Act, an applicant may appeal a Commissioner’s refusal to the Federal Court of Canada. The public record of this CIPO proceeding does not indicate whether Nestlé has filed or intends to file such an appeal. Monitoring Federal Court filings is advisable for parties tracking this matter.
Anticipation under s.28.2(1)(b) requires that a single prior art disclosure fully disclosed the claimed invention before the claim date in a manner enabling a skilled person to practise it. Obviousness under s.28.3 asks whether the claimed invention would have been plain and obvious to a person skilled in the art at the relevant date. Both findings were made against Nestlé’s claims in CA2912957A1.
Under subsection 86(11) of the Patent Rules, an applicant may propose amendments at the Patent Appeal Board stage only if they are ‘necessary’ to make the application allowable. The Board found Nestlé’s proposed amendments did not cure the anticipation and obviousness defects, meaning they were not necessary amendments. This closed off the amendment pathway within the CIPO process, leaving Federal Court appeal as the only remaining option.
PatSnap Eureka searches patents and litigation data to answer instantly.